Researchers have demonstrated that cysteinase, a new drug compound, can starve pancreatic cells of cysteine supply, causing ferroptosis.
List view / Grid view
Filter the results
Researchers have developed two small molecules which target two components of the circadian rhythm and could be used to lengthen the body clock.
In light of the COVID-19 pandemic, the creators of the Clinical Research Navigator (CRN) tool have offered free access to their system for biomedical researchers.
A lead COVID-19 vaccine candidate has been selected by Johnson & Johnson, after demonstrating promise in pre-clinical testing.
A new compound, called FL118, was effective at combatting multiple myeloma in advanced stages of the condition in patient samples as well as mice, say researchers.
A review of potential COVID-19 therapeutics revealed that the most effective are likely to be those directly targeting SARS-CoV-2, such as remdesivir and tilarone.
Researchers have revealed a new substance that can bind well to serotonin transporters, offering a potential way to lessen the side effects of antidepressant therapies.
A team of Russian scientists has suggested a new method to measure the sizes of atoms as well as their intermolecular interactions, which they say could help drug design.
Researchers have shown that incorporating noncanonical amino acids (ncAAs) in phage display expands the range of peptides it can identify.
Researchers have demonstrated that in mice, a newly developed heparan sulfate molecule can provide an effective alternative treatment for overdoses of acetaminophen.
A star-shaped molecule along with a modified platinum drug have demonstrated success at combatting tumours with few toxic effects in mice.
New in silico screening software has the capability to screen billions of compounds, with the hope of improving drug design and limiting side effects.
The first drug designed using artificial intelligence (AI) has moved into its Phase I trial. Professor Andrew Hopkins of Exscientia explains how an algorithm was used to achieve this milestone.
Researchers show Naphthyridine-Azaquinolone (NA) could be a possible future therapy able to slow the progression and improve the symptoms of Huntington’s disease.
Upregulating utrophin using small molecules could be a new therapeutic approach for Duchenne muscular dystrophy (DMD).